Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Patients With Cancer and Diabetes.

Key Points

• To determine the safety and efficacy of SGLT2 inhibitors in patients with both diabetes and cancer.
• Review of clinical evidence regarding SGLT2 inhibitors
• Assessment of mortality rates in diagnosed patients
• Identification of mechanisms related to the effects observed
• SGLT2 inhibitors were linked to reduced all-cause mortality among patients with diabetes and cancer.
• Need for further randomized clinical trials to validate findings and clarify mechanisms.